Angeles Funding Advisors LLC lowered its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 46.3% within the second quarter, based on its most up-to-date submitting with the SEC. The fund owned 1,644 shares of the corporate’s inventory after promoting 1,415 shares throughout the interval. Angeles Funding Advisors LLC’s holdings in AbbVie have been price $282,000 as of its most up-to-date SEC submitting.
Quite a lot of different hedge funds additionally lately made adjustments to their positions in ABBV. Vermillion & White Wealth Administration Group LLC purchased a brand new stake in AbbVie within the fourth quarter price $26,000. Ridgewood Investments LLC purchased a brand new stake in AbbVie within the second quarter price $27,000. Ready Wealth Administration LLC purchased a brand new stake in AbbVie within the fourth quarter price $33,000. IFS Advisors LLC purchased a brand new stake in AbbVie within the first quarter price $36,000. Lastly, Quest Companions LLC lifted its stake in AbbVie by 4,140.0% within the second quarter. Quest Companions LLC now owns 212 shares of the corporate’s inventory price $36,000 after buying a further 207 shares over the last quarter. 70.23% of the inventory is owned by institutional traders.
AbbVie Value Efficiency
Shares of ABBV opened at $195.78 on Tuesday. The inventory has a market cap of $345.72 billion, a PE ratio of 58.09, a price-to-earnings-growth ratio of two.66 and a beta of 0.64. The corporate has a debt-to-equity ratio of 8.51, a fast ratio of 0.71 and a present ratio of 0.81. AbbVie Inc. has a fifty-two week low of $135.85 and a fifty-two week excessive of $199.95. The agency’s 50-day easy transferring common is $187.41 and its two-hundred day easy transferring common is $175.36.
AbbVie (NYSE:ABBV – Get Free Report) final introduced its quarterly earnings knowledge on Thursday, July twenty fifth. The corporate reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.08. The enterprise had income of $14.46 billion for the quarter, in comparison with analysts’ expectations of $14.02 billion. AbbVie had a web margin of 9.71% and a return on fairness of 203.66%. The enterprise’s income was up 4.3% in comparison with the identical quarter final yr. Throughout the identical quarter within the prior yr, the corporate earned $2.91 earnings per share. Analysts anticipate that AbbVie Inc. will put up 10.86 earnings per share for the present fiscal yr.
AbbVie Dividend Announcement
The corporate additionally lately introduced a quarterly dividend, which might be paid on Friday, November fifteenth. Stockholders of report on Tuesday, October fifteenth might be paid a $1.55 dividend. The ex-dividend date is Tuesday, October fifteenth. This represents a $6.20 annualized dividend and a dividend yield of three.17%. AbbVie’s dividend payout ratio is presently 183.98%.
Analysts Set New Value Targets
A number of analysts have weighed in on the inventory. Wells Fargo & Firm boosted their value goal on shares of AbbVie from $200.00 to $205.00 and gave the inventory an “obese” ranking in a analysis be aware on Friday, July twenty sixth. William Blair raised shares of AbbVie to a “strong-buy” ranking in a analysis be aware on Friday, August thirtieth. Piper Sandler upped their value goal on shares of AbbVie from $196.00 to $209.00 and gave the corporate an “obese” ranking in a analysis be aware on Friday, August twenty third. HSBC raised shares of AbbVie from a “maintain” ranking to a “purchase” ranking and set a $185.00 value goal for the corporate in a analysis be aware on Wednesday, June fifth. Lastly, BMO Capital Markets upped their value goal on shares of AbbVie from $180.00 to $214.00 and gave the corporate an “outperform” ranking in a analysis be aware on Friday, July nineteenth. Two funding analysts have rated the inventory with a maintain ranking, twelve have assigned a purchase ranking and two have given a robust purchase ranking to the corporate. Based on knowledge from MarketBeat.com, AbbVie presently has a consensus ranking of “Purchase” and a mean goal value of $191.64.
View Our Newest Analysis Report on AbbVie
Insider Transactions at AbbVie
In associated information, Chairman Richard A. Gonzalez offered 282,845 shares of the inventory in a transaction that occurred on Wednesday, July seventeenth. The shares have been offered at a mean value of $175.00, for a complete transaction of $49,497,875.00. Following the transaction, the chairman now owns 513,099 shares within the firm, valued at $89,792,325. The sale was disclosed in a authorized submitting with the SEC, which could be accessed by means of the SEC web site. In different AbbVie information, Chairman Richard A. Gonzalez offered 282,845 shares of the inventory in a transaction that occurred on Wednesday, July seventeenth. The shares have been offered at a mean value of $175.00, for a complete worth of $49,497,875.00. Following the transaction, the chairman now straight owns 513,099 shares within the firm, valued at $89,792,325. The transaction was disclosed in a authorized submitting with the Securities & Alternate Fee, which could be accessed by means of this hyperlink. Additionally, Chairman Richard A. Gonzalez offered 66,500 shares of the inventory in a transaction on Monday, August fifth. The inventory was offered at a mean value of $186.52, for a complete transaction of $12,403,580.00. Following the completion of the sale, the chairman now straight owns 446,599 shares of the corporate’s inventory, valued at $83,299,645.48. The disclosure for this sale could be discovered right here. Insiders personal 0.25% of the corporate’s inventory.
AbbVie Firm Profile
AbbVie Inc discovers, develops, manufactures, and sells prescription drugs worldwide. The corporate gives Humira, an injection for autoimmune and intestinal Behçet’s illnesses, and pyoderma gangrenosum; Skyrizi to deal with reasonable to extreme plaque psoriasis, psoriatic illness, and Crohn’s illness; Rinvoq to deal with rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn’s illness; Imbruvica for the therapy of grownup sufferers with blood cancers; Epkinly to deal with lymphoma; Elahere to deal with most cancers; and Venclexta/Venclyxto to deal with blood cancers.
Featured Tales
Need to see what different hedge funds are holding ABBV? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Obtain Information & Rankings for AbbVie Day by day – Enter your e mail handle under to obtain a concise each day abstract of the newest information and analysts’ rankings for AbbVie and associated firms with MarketBeat.com’s FREE each day e mail e-newsletter.
